Compass Pathways CEO Kabir Nath on Trump order to speed psychedelic research and FDA access vouchers

Psychedelic research and access gained momentum after US President Donald Trump signed an executive order aimed at accelerating reviews. The order directs the FDA to provide expedited review vouchers for psychedelics that have a breakthrough designation, cutting review timelines to around one to two months from roughly six to ten months. Market reactions followed immediately, with shares tied to psychedelic therapies jumping. Compass Pathways rose as much as 53%, while AtaiBeckley gained around 37%, GH Research climbed about 34%, and Definium Therapeutics rallied roughly 16%. The AdvisorShares Psychedelics ETF (PSIL) also surged, reaching a highest intraday level since July 2023. Compass Pathways CEO Kabir Nath discusses the implications on Bloomberg Businessweek Daily alongside hosts Carol Massar and Tim Stenovec, linking the regulatory shift to expected benefits for companies with breakthrough-designated therapies.